SIGA Technologies, Inc.

SIGA

US8269171067

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
7.75 ^USD	+3.33%		-17.90%	+38.39%

05-07	Earnings Flash (SIGA) SIGA TECHNOLOGIES Reports Q1 Revenue $25.4M	MT
05-07	Transcript : SIGA Technologies, Inc., Q1 2024 Earnings Call, May 07, 2024

SIGA Technologies, Inc. Announces Resignation of Robin E. Abrams as the General Counsel and Chief Administrative Officer, Effective April 15, 2022

March 24, 2022 at 09:11 pm

On March 18, 2022, Robin E. Abrams tendered her resignation as the General Counsel and Chief Administrative Officer of SIGA Technologies, Inc, effective April 15, 2022, to pursue other opportunities. Ms. Abrams did not resign as a result of any disagreement with the company on any matter relating to the company's operations, policies or practices.

Latest news about SIGA Technologies, Inc.

Earnings Flash (SIGA) SIGA TECHNOLOGIES Reports Q1 Revenue $25.4M	05-07	MT
Transcript : SIGA Technologies, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
SIGA Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
SIGA Technologies to Drive International Promotion for Oral TPOXX in Amended Deal With Meridian Medical	04-01	MT
SIGA Technologies, Inc. Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX	04-01	CI
SIGA Technologies, Inc. Announces the Appointment of Larry Miller as General Counsel	03-25	CI
North American Morning Briefing : Stock Futures Flat After S&P 500 Hit Record High	03-13	DJ
Tranche Update on SIGA Technologies, Inc.'s Equity Buyback Plan announced on August 5, 2021.	03-12	CI
SIGA Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
Transcript : SIGA Technologies, Inc., Q4 2023 Earnings Call, Mar 12, 2024	03-12
Sector Update: Health Care Stocks Rise Late Afternoon	03-12	MT
SIGA Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-12	CI
SIGA Technologies Share Rise After Special Cash Dividend Announcement	03-12	MT
Siga Technologies, Inc. Declares A Special Cash Dividend, Payable on April 11, 2024	03-12	CI
SIGA Technologies Names Diem Nguyen as Chief Executive	01-22	MT
Siga Technologies, Inc. Appoints Diem Nguyen to the Board of Directors	01-22	CI
SIGA Technologies, Inc. Announces CEO Changes	01-22	CI
SIGA Technologies, Inc.'s Equity Buyback announced on August 5, 2021, has expired with 4,152,118 shares, representing 5.69% for $28.49 million.	12-30	CI
Stigma, regulatory barriers delay mpox response in country that needs it most	12-05	RE
SIGA Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Earnings Flash (SIGA) SIGA TECHNOLOGIES Posts Q3 Revenue $9.2M	11-07	MT
Transcript : SIGA Technologies, Inc., Q3 2023 Earnings Call, Nov 07, 2023	11-07
Tranche Update on SIGA Technologies, Inc.'s Equity Buyback Plan announced on August 5, 2021.	11-07	CI
SIGA Says European Commission Forms Procurement Mechanism For Oral TPOXX	23/10/23	MT
SIGA Technologies, Inc. Appoints Jay K. Varma as EVP and Chief Medical Officer	06/09/23	CI

Chart SIGA Technologies, Inc.

Duration

Period

More charts

Company Profile

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The Company's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. It uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.

Sector

Pharmaceuticals

Calendar

11/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for SIGA Technologies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SIGA TECHNOLOGIES, INC.	+38.39%	551M
ELI LILLY AND COMPANY	+32.36%	695B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	361B
MERCK & CO., INC.	+19.46%	330B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.34%	239B
NOVARTIS AG	+6.68%	204B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.62%	168B

Other Pharmaceuticals